AF
SNDX icon

Amalgamated Financial’s Syndax Pharmaceuticals SNDX Stock Holding History

Amalgamated Financial’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$102K Buy
+5,880
New +$99K ﹤0.01% 2142

Other funds holding SNDX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Amalgamated Financial's SNDX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Syndax Pharmaceuticals (SNDX) in Q1 2022: 5,880 shares worth $102K. The stake represents ﹤0.01% of the portfolio and ranks #2142 among its holdings.

136 funds tracked by Wall St. Rank hold SNDX as of Q1 2022.

  • Amalgamated Financial held 5,880 shares of Syndax Pharmaceuticals worth $102K as of Q1 2022.
  • Syndax Pharmaceuticals was a new Amalgamated Financial position in Q1 2022.
  • Syndax Pharmaceuticals made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2142 holding.
  • 136 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.